Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SpyGlass PharmaSGP -0.59%12 Quick Ratio is 25.06 as of Jun. 2026, which is 38% above its 10-year median of 18.11. GuruFocus rates SGP with a GF Score™ of 12/100. Among 1,405 Biotechnology companies, SpyGlass Pharma ranks better than 97.72% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. SpyGlass Pharma's quick ratio for the quarter that ended in Jun. 2026 was 25.06.
SpyGlass Pharma has a quick ratio of 25.06. It generally indicates good short-term financial strength.
The historical rank and industry rank for SpyGlass Pharma's Quick Ratio or its related term are showing as below:
SGP'
s Quick Ratio Range Over the Past 10 Years
Min: 2.23 Med: 18.11 Max: 38
Current: 38
During the past 3 years, SpyGlass Pharma's highest Quick Ratio was 38.00. The lowest was 2.23. And the median was 18.11.
SGP's Quick Ratio is ranked better than 97.72% of 1405
companies
in the Biotechnology industry
Industry Median: 3.5
vs SGP: 38.00
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
SpyGlass Pharma Quick Ratio Related Terms
SpyGlass Pharma Quick Ratio Historical Data
* Premium members only.
The historical data trend for SpyGlass Pharma's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, SpyGlass Pharma's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SpyGlass Pharma Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SpyGlass Pharma's Quick Ratio distribution charts can be found below:
* The bar in red indicates where SpyGlass Pharma's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
SpyGlass Pharma's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SpyGlass Pharma (SGP) has a Quick Ratio of 25.06 as of Jun. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on SpyGlass Pharma and its competitors. This is 38% above median its historical median of 18.11. Over the past decade, SpyGlass Pharma's Quick Ratio has ranged from 2.23 to 38.00. According to the industry distribution chart, SpyGlass Pharma ranks #32 out of 1405 companies in the Biotechnology industry, placing it in the top 2.3%.
Is SpyGlass Pharma's Quick Ratio too high?
SpyGlass Pharma's current Quick Ratio of 25.06 is 38% above median its 10-year median of 18.11. Over the past 10 years, this metric has ranged from a low of 2.23 to a high of 38.00. The Biotechnology industry median Quick Ratio is 3.50. SpyGlass Pharma's value of 25.06 is 616% above this industry median. Based on the distribution chart, SpyGlass Pharma ranks #32 out of 1405 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, SpyGlass Pharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does SpyGlass Pharma's Quick Ratio compare to RIGL and NGNE?
According to the Biotechnology industry distribution chart, SpyGlass Pharma ranks #32 out of 1405 companies for Quick Ratio. This places SpyGlass Pharma in the top 2% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.50. SpyGlass Pharma's value of 25.06 is 616% above this benchmark. Historically, SpyGlass Pharma's own Quick Ratio has ranged from 2.23 to 38.00 over the past decade. While the company's 10-year median is 18.11 vs. the industry median of 3.50, SpyGlass Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.50, based on 1,405 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SpyGlass Pharma's current Quick Ratio of 25.06 is 616% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on SpyGlass Pharma and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SpyGlass Pharma's current Quick Ratio is 25.06, which is 38% above median its own 10-year median of 18.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SpyGlass Pharma stock overvalued right now?
SpyGlass Pharma (SGP) has a current Quick Ratio of 25.06. The current Quick Ratio is 25.06, which is 38% above median its 10-year median of 18.11 and 616% above the Biotechnology industry median of 3.50. SpyGlass Pharma's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For SpyGlass Pharma (SGP), the current Quick Ratio is 25.06 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
12GF Score
Get the complete analysis for SGP
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGP has been successfully added to your 
